Sermo's new CEO vows to expand physician community

Share this article:

Former Revolution Health president Tim Davenport is taking over as CEO of the physician network Sermo, the company announced Wednesday. His previous experience includes serving as an adviser to the chat tech startup Yobongo and as CEO of the investment firm Vastera.

Davenport's arrival fills a gap created when founder Dr. Daniel Palestrant and chief medical officer Dr. Adam Sharp left in November to launch the startup Par8o.

Davenport told MM&M that Sermo is in a prime position to make itself an integral physician resource, and that internal research that showed Sermo, along with Facebook and YouTube, was among the best known brands for doing professional work online.

He said experience in building consumer communities is among the assets he brings to the company and that the “lessons are what did it take to evolve a vibrant online community,” which he described as “probably more of an art than a science.”

Davenport said understanding what makes Sermo's community interactions valuable is part of this process and that the company is “still in the earliest days of figuring out how exactly we structure those experiences.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...